[
  {
    "ts": "2025-11-06T05:00:52+00:00",
    "headline": "McKesson Corp (MCK) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised Earnings ...",
    "summary": "McKesson Corp (MCK) reports a 10% revenue increase and raises earnings guidance, despite challenges in the medical surgical solutions segment.",
    "url": "https://finance.yahoo.com/news/mckesson-corp-mck-q2-2026-050052711.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "67bce190-6475-380e-9c57-65e9cf19fa9f",
      "content": {
        "id": "67bce190-6475-380e-9c57-65e9cf19fa9f",
        "contentType": "STORY",
        "title": "McKesson Corp (MCK) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised Earnings ...",
        "description": "",
        "summary": "McKesson Corp (MCK) reports a 10% revenue increase and raises earnings guidance, despite challenges in the medical surgical solutions segment.",
        "pubDate": "2025-11-06T05:00:52Z",
        "displayTime": "2025-11-06T05:00:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/bc899ad9fd4b953f1fb4b1b8fb03f634",
          "originalWidth": 180,
          "originalHeight": 180,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n_bIrfymbS_e4aODmo3bQA--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/bc899ad9fd4b953f1fb4b1b8fb03f634.cf.webp",
              "width": 180,
              "height": 180,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_yyDr09n48tSiqr_6kDnag--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/bc899ad9fd4b953f1fb4b1b8fb03f634.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mckesson-corp-mck-q2-2026-050052711.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mckesson-corp-mck-q2-2026-050052711.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MCK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T13:00:00+00:00",
    "headline": "Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results",
    "summary": "Quarterly Revenue Growth of 13% to ~$68 Million Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up SAN CARLOS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering nove",
    "url": "https://finance.yahoo.com/news/iovance-biotherapeutics-highlights-business-achievements-130000301.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "f686e85c-c2aa-31ef-8922-a7fc62162d75",
      "content": {
        "id": "f686e85c-c2aa-31ef-8922-a7fc62162d75",
        "contentType": "STORY",
        "title": "Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results",
        "description": "",
        "summary": "Quarterly Revenue Growth of 13% to ~$68 Million Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up SAN CARLOS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering nove",
        "pubDate": "2025-11-06T13:00:00Z",
        "displayTime": "2025-11-06T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/cedc32b016b8dc2392e47b634c25fda0",
          "originalWidth": 418,
          "originalHeight": 137,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nnbHJYt2Jr1apRM.KiTLiA--~B/aD0xMzc7dz00MTg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/cedc32b016b8dc2392e47b634c25fda0.cf.webp",
              "width": 418,
              "height": 137,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E8Snnw7QEiaPKF2FL8FMyw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/cedc32b016b8dc2392e47b634c25fda0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/iovance-biotherapeutics-highlights-business-achievements-130000301.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/iovance-biotherapeutics-highlights-business-achievements-130000301.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IOVA"
            },
            {
              "symbol": "MCK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T13:00:00+00:00",
    "headline": "PRISM Vision Group Marks Milestone in National Expansion with Spokane Eye Clinic Affiliation",
    "summary": "NEW PROVIDENCE, N.J., November 06, 2025--PRISM Vision Group closed a transaction with Spokane Eye Clinic, through which Spokane Eye Clinic joins PRISM’s network of affiliated practices.",
    "url": "https://finance.yahoo.com/news/prism-vision-group-marks-milestone-130000863.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "d9963fd0-23ef-375e-9e0c-ea168eb717c5",
      "content": {
        "id": "d9963fd0-23ef-375e-9e0c-ea168eb717c5",
        "contentType": "STORY",
        "title": "PRISM Vision Group Marks Milestone in National Expansion with Spokane Eye Clinic Affiliation",
        "description": "",
        "summary": "NEW PROVIDENCE, N.J., November 06, 2025--PRISM Vision Group closed a transaction with Spokane Eye Clinic, through which Spokane Eye Clinic joins PRISM’s network of affiliated practices.",
        "pubDate": "2025-11-06T13:00:00Z",
        "displayTime": "2025-11-06T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/ea8fe831bb5f50c79bab5b734bdb8b64",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4e1IMXokXXPvTR2IEJvK5w--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ea8fe831bb5f50c79bab5b734bdb8b64.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o31kBF6KHcOzcNGKIrCemQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ea8fe831bb5f50c79bab5b734bdb8b64.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/prism-vision-group-marks-milestone-130000863.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prism-vision-group-marks-milestone-130000863.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MCK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]